Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug [Yahoo! Finance]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains? [Yahoo! Finance]
Iovance Biotherapeutics (IOVA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.